Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sutro Biopharma (STRO) Return on Assets (2018 - 2025)

Sutro Biopharma's Return on Assets history spans 8 years, with the latest figure at 0.86% for Q3 2025.

  • For Q3 2025, Return on Assets fell 60.0% year-over-year to 0.86%; the TTM value through Sep 2025 reached 0.86%, down 60.0%, while the annual FY2024 figure was 0.53%, 29.0% down from the prior year.
  • Return on Assets for Q3 2025 was 0.86% at Sutro Biopharma, down from 0.69% in the prior quarter.
  • Across five years, Return on Assets topped out at 0.18% in Q2 2021 and bottomed at 0.86% in Q3 2025.
  • The 5-year median for Return on Assets is 0.31% (2022), against an average of 0.38%.
  • The largest annual shift saw Return on Assets rose 18bps in 2021 before it crashed -60bps in 2025.
  • A 5-year view of Return on Assets shows it stood at 0.28% in 2021, then dropped by -6bps to 0.3% in 2022, then grew by 20bps to 0.24% in 2023, then crashed by -129bps to 0.54% in 2024, then plummeted by -59bps to 0.86% in 2025.
  • Per Business Quant, the three most recent readings for STRO's Return on Assets are 0.86% (Q3 2025), 0.69% (Q2 2025), and 0.67% (Q1 2025).